B. 1. Inca, La situation du cancer en France en 2012 Disponible sur: http://www.ecancer.fr/toutes-les-actualites/7281-publication-du-rapport-sur-la-situation-du-cancer-en- france-en-2012, 2013.

. La-longue-naissance-d-'un-médicament, Disponible sur: http://www.interpharma.ch/fr/faits-et-statistiques/2830-la-longue-naissance-dun- medicament, 2013.

C. Ich, ICH topic E8. General condiserations for clinical trials, 1997.

L. Culine, Mémento de la recherche biomédicale portant sur un médicament à usage humain, 2012.

A. Bhatt, Evolution of Clinical Research: A History Before and Beyond James Lind

P. Amiel, Des cobayes et des hommes Expérimentation sur l'être humain et justice

. Paris, Les Belles Lettres, 2011.

. Association-médicale-mondiale, Déclaration d'Helsinki de l'AMM -Principes éthiques applicables à la recherche médicale impliquant des êtres humains, 2008.

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2
DOI : 10.1016/j.ejca.2008.10.026

E. /. Chmp, Guideline on the evaluation of anticancer medicinal products in man, 2012.

P. Wen, D. Macdonald, D. Reardon, T. Cloughesy, A. Sorensen et al., Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-72, 2010.
DOI : 10.1200/JCO.2009.26.3541

N. Lassau, A. Brule, L. Chami, B. Benatsou, P. Peronneau et al., ??valuation pr??coce des traitements anti-angiog??niques par ??chographie dynamique de contraste, Journal de Radiologie, vol.89, issue.5, pp.549-55, 2008.
DOI : 10.1016/S0221-0363(08)71480-X

J. Wolchok, A. Hoos, O. Day, S. Weber, J. Hamid et al., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009.
DOI : 10.1158/1078-0432.CCR-09-1624

A. Du, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4 Disponible sur: http://evs.nci.nih.gov/ftp1 mélanome cutané en France métropolitaine -Incidence et mortalité 2011, Disponible sur, 2006.

E. Ghissassi, F. Baan, R. Straif, K. Grosse, Y. Secretan et al., A review of human carcinogens???Part D: radiation, The Lancet Oncology, vol.10, issue.8, pp.751-753, 2009.
DOI : 10.1016/S1470-2045(09)70213-X

V. Bataille and E. De-vries, Melanoma--Part 1: epidemiology, risk factors, and prevention, BMJ, vol.337, issue.nov20 1, p.2249, 2008.
DOI : 10.1136/bmj.a2249

URL : https://repub.eur.nl/pub/32363/113.pdf

S. Gandini, F. Sera, M. Cattaruzza, P. Pasquini, O. Picconi et al., Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure, European Journal of Cancer, vol.41, issue.1, pp.45-60, 2005.
DOI : 10.1016/j.ejca.2004.10.016

L. Dennis, M. Vanbeek, B. Freeman, L. Smith, B. Dawson et al., Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive metaanalysis Ultraviolet radiation and melanoma, Ann Epidemiol. Semin Cutan Med Surg, vol.1830, issue.304, pp.614-27222, 2008.

S. Gandini, F. Sera, M. Cattaruzza, P. Pasquini, R. Zanetti et al., Metaanalysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling, Eur J Cancer. Int J Cancer, vol.41127, issue.3210, pp.2040-592430, 2005.

E. Psaty, A. Scope, A. Halpern, and A. Marghoob, Defining the patient at high risk for melanoma, International Journal of Dermatology, vol.92, issue.4, pp.362-76, 2010.
DOI : 10.1111/j.1365-4632.2010.04381.x

S. Gandini, F. Sera, M. Cattaruzza, P. Pasquini, D. Abeni et al., Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi, European Journal of Cancer, vol.41, issue.1, pp.28-44, 2005.
DOI : 10.1016/j.ejca.2004.10.015

W. Tuong, L. Cheng, and A. Armstrong, Melanoma, Dermatol Clin, vol.30, issue.1, 2012.
DOI : 10.1016/B978-1-4160-6643-9.00035-7

G. Tomasic, Mélanomes cutanés. RéfleXions en Médecine Oncologique, pp.4-5, 2010.

L. Duncan, C. Balch, J. Gershenwald, S. Soong, J. Thompson et al., The classification of cutaneous melanoma501-13, ix. 40 Final version of 2009 AJCC melanoma staging and classification, Hematol Oncol Clin North Am. J Clin Oncol, vol.2327, issue.336, pp.6199-206, 2006.

M. Richard, Epidémiologie du mélanome et application au dépistage précoce. La lettre du cancérologue, pp.81-86, 2009.

R. Friedman, D. Rigel, and A. Kopf, Early Detection of Malignant Melanoma: The Role of Physician Examination and Self-Examination of the Skin, CA: A Cancer Journal for Clinicians, vol.35, issue.3, pp.130-51, 1985.
DOI : 10.3322/canjclin.35.3.130

N. Abbasi, H. Shaw, D. Rigel, R. Friedman, W. Mccarthy et al., Early Diagnosis of Cutaneous Melanoma, JAMA, vol.292, issue.22, pp.2771-2777, 2004.
DOI : 10.1001/jama.292.22.2771

R. Mackie, Clinical recognition of early invasive malignant melanoma., BMJ, vol.301, issue.6759, pp.1005-1011, 1990.
DOI : 10.1136/bmj.301.6759.1005

J. Gachon, P. Beaulieu, J. Sei, J. Gouvernet, J. Claudel et al., First prospective study of the recognition process of melanoma in dermatological practice434-8. 48. INCa. Mise à jour 2011 des comptes rendus d'anatomopathologie : données minimales à renseigner pour une tumeur primitive. Disponible sur, Arch Dermatol, vol.141, issue.4, 2005.

S. Négrier, P. Saiag, B. Guillot, O. Verola, M. Avril et al., Recommandations pour la Pratique Clinique : Standards, Options et Recommandations 2005 pour la prise en charge des patients adultes atteints d???un m??lanome cutan?? MO Texte court, Annales de Dermatologie et de V??n??r??ologie, vol.132, issue.12, pp.79-85, 2005.
DOI : 10.1016/S0151-9638(05)79609-5

S. Pasquali and S. Mocellin, The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma, Current Medicinal Chemistry, vol.17, issue.29, pp.3327-3363, 2010.
DOI : 10.2174/092986710793176393

N. Cascinelli, F. Belli, R. Mackie, M. Santinami, R. Bufalino et al., Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis, Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial, pp.866-875, 2001.

J. Kirkwood, J. Ibrahim, V. Sondak, J. Richards, L. Flaherty et al., High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190, Journal of Clinical Oncology, vol.18, issue.12, pp.2444-58, 2000.
DOI : 10.1200/JCO.2000.18.12.2444

B. Brihaye and T. Papo, Interférons : utilisation thérapeutique. Traités EMC, 2009.

D. Coit, R. Andtbacka, C. Anker, C. K. Bichakjian, and W. Carson, Journal of the National Comprehensive Cancer Network, 2012.

M. Middleton, J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen et al., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years, J Clin Oncol. Eur J Cancer, vol.1840, issue.112, pp.158-661825, 2000.

B. Chabner, T. Roberts, and J. , Timeline: Chemotherapy and the war on cancer, Nature Reviews Cancer, vol.17, issue.1, pp.65-72, 2005.
DOI : 10.1056/NEJM199610033351408

J. Dimasi, R. Hansen, and H. Grabowski, The price of innovation: new estimates of drug development costs, Journal of Health Economics, vol.22, issue.2, pp.151-85, 2003.
DOI : 10.1016/S0167-6296(02)00126-1

T. Bogenrieder and M. Herlyn, The molecular pathology of cutaneous melanoma, Cancer Biomarkers, vol.9, issue.1-6
DOI : 10.3233/CBM-2011-0164

C. Longvert and L. Larue, BRAF: biologie et fonction, Correspondance en Onco- Théranostic, vol.1, pp.14-22, 2012.

M. Brose, P. Volpe, M. Feldman, M. Kumar, I. Rishi et al., BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res, vol.62, issue.23, pp.6997-7000, 2002.

J. Jakob, R. Basset, C. Ng, A. Lazar, and G. Alvarado, mutations in metastatic melanoma., Journal of Clinical Oncology, vol.29, issue.15_suppl, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.8500

V. Nikolaou, A. Stratigos, K. Flaherty, and H. Tsao, Melanoma: New Insights and New Therapies, Journal of Investigative Dermatology, vol.132, issue.3, pp.854-63, 2012.
DOI : 10.1038/jid.2011.421

H. Davies, G. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, 2002.
DOI : 10.1006/geno.2000.6354

K. Flaherty, I. Puzanov, K. Kim, A. Ribas, G. Mcarthur et al., Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-828, 2010.
DOI : 10.1056/NEJMoa1002011

J. Sosman, K. Kim, L. Schuchter, R. Gonzalez, A. Pavlick et al., Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, pp.707-721, 2012.
DOI : 10.1056/NEJMoa1112302

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011.
DOI : 10.1056/NEJMoa1103782

A. Menzies, G. Long, and R. Murali, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Dabrafenib and its potential for the treatment of metastatic melanoma, Lancet. Drug Des Devel Ther, vol.3806, issue.82, pp.358-65391, 2012.

N. Wagle, C. Emery, M. Berger, M. Davis, A. Sawyer et al., Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling, Journal of Clinical Oncology, vol.29, issue.22, pp.3085-96, 2011.
DOI : 10.1200/JCO.2010.33.2312

R. Nazarian, H. Shi, Q. Wang, X. Kong, R. Koya et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.66, issue.7326, pp.973-980, 2010.
DOI : 10.1038/nature09626

C. Johannessen, J. Boehm, S. Kim, S. Thomas, L. Wardwell et al., COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, vol.21, issue.7326, pp.968-72, 2010.
DOI : 10.1038/nature09627

P. Safety, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial, Lancet Oncol, vol.13, issue.8, pp.773-81, 2012.

G. Falchook, K. Lewis, J. Infante, M. Gordon, N. Vogelzang et al., Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial, Melanoma and immunotherapy, pp.782-9547, 2009.
DOI : 10.1016/S1470-2045(12)70269-3

T. Blanchard, P. Srivastava, and F. Duan, Vaccines against advanced melanoma, Clinics in Dermatology, vol.31, issue.2, pp.179-90, 2013.
DOI : 10.1016/j.clindermatol.2012.08.005

L. Gal and F. , Traitement du mélanome: immunothérapie cellulaire, Med Ther, vol.6, issue.6, pp.487-93, 2000.

B. Merelli, D. Massi, L. Cattaneo, and M. Mandala, Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities, Critical Reviews in Oncology/Hematology, vol.89, issue.1, 2013.
DOI : 10.1016/j.critrevonc.2013.08.002

C. Robert and F. Ghiringhelli, What Is the Role of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?, The Oncologist, vol.14, issue.8, pp.848-61, 2009.
DOI : 10.1634/theoncologist.2009-0028

E. Ileana, S. Champiat, and J. Soria, Immune-checkpoints: the new anti-cancer immunotherapies], Bull Cancer, vol.100, issue.6, pp.601-611, 2013.

. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.366, issue.26, pp.2443-54, 2012.

O. Hamid, C. Robert, A. Daud, F. Hodi, W. Hwu et al., Safety and Tumor Responses with Lambrolizumab (Anti???PD-1) in Melanoma, New England Journal of Medicine, vol.369, issue.2, pp.134-178, 2013.
DOI : 10.1056/NEJMoa1305133

N. Circulaire, . Inca, and . Moprc, relative au soutien apporté par l'Institut national du cancer à l'organisation des essais cliniques en cancérologie. 98, 2006.

A. Ministère, . Sociales, . De, and . Santé, Les missions d'enseignement, de recherche, de référence et d'innovation (MERRI) Disponible sur: http://www.sante.gouv.fr/les-missions-d-enseignement-de-recherche-de-reference-et-dinnovation-merri .html. Dernière consultation le, 2013.